Expertise in
4
conditions

Enrico Montefusco

Rome, IT 
Expertise in
4
conditions
Rome, IT 

Overview

Enrico Montefusco practices practicing medicine in Rome, Italy.

Mr. Montefusco is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Chronic Myelogenous Leukemia (CML), Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Enrollment Status: Completed
Publish Date: April 18, 2025
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.
Enrollment Status: Unknown
Publish Date: January 05, 2022
Intervention Type: Behavioral
View 2 Less Clinical Trials

20 Total Publications

Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols.
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols.
Journal: Acta oncologica (Stockholm, Sweden)
Published: August 31, 2021

Frequently Asked Questions about Enrico Montefusco

Is Enrico Montefusco a top-rated expert for Essential Thrombocythemia?

MediFind is an objective health platform that identifies experts based on real-world data. Enrico Montefusco is classified as an Distinguished expert for Essential Thrombocythemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Enrico Montefusco participate in research or clinical trials?

Yes. Enrico Montefusco has published 20 articles and abstracts on conditions like Essential Thrombocythemia. You can view a list of Enrico Montefusco's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Montefusco's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile